Filing Details
- Accession Number:
- 0001209191-21-016029
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-02 16:36:27
- Reporting Period:
- 2021-02-26
- Accepted Time:
- 2021-03-02 16:36:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1446847 | Ironwood Pharmaceuticals Inc | IRWD | Pharmaceutical Preparations (2834) | 043404176 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1808510 | Conor Kilroy | C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110 | Svp, Gc & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2021-02-26 | 1,399 | $9.11 | 127,926 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-02-26 | 1,474 | $9.11 | 126,452 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-02-26 | 2,268 | $9.11 | 124,184 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-02-26 | 1,848 | $9.11 | 122,336 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February27, 2017.
- The reporting person acquired 492 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2020.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 15, 2018.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January29, 2019.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.